Novavax Stock: Buy at the High?
Of all the rags to riches stories that the pandemic has fueled for drugmakers, few are as incredible as Novavax (NASDAQ: NVAX). Shares are up about 2,500% from the beginning of the year. After the surge, should investors pass or should they buy at the high?
Image source: Getty Images.
Admittedly, the stock isn't near it's all-time high. Shares peaked around $180 briefly this summer, after the company became part of the U.S. government's Operation Warp Speed (OWS) and management announced positive phase 1 data from trials of its vaccine candidate.
Source Fool.com
